Amicus Therapeutics: No Disease is Too Small

Rare diseases are sadly put on the sideline by most pharmaceutical companies due to the small number of people requiring treatment. Amicus Therapeutics sees an opportunity here and has decided to make a difference. Amicus Therapeutics was founded February 4th, 2002 in Cranbury, New Jersey and headed by John Crowley (CEO), Bradley Campbell (COO), and William Baird (CFO). Amicus Therapeutics focuses on rare diseases, sometimes called orphan diseases. Read the company profile at Crunchbase.

Orphan diseases are any disease that affects a very small number of people. Since Orphan diseases lack a reasonable market value due to low demand, it is difficult for companies to invest resources into research with the aim of discovering treatments or cures. Amicus Therapeutics biggest development is Migalastat, also known as Galafold. Migalastat is a drug used in the long-term treatment of Fabry disease.


Amicus Therapeutics has seen a substantial rise in stock value over the 2017 fiscal year. Their innovative approach to research and development has put them ahead of the competition. Amicus Therapeutics has a strong sense of commitment and compassion for the people who are relying on their research and development. They know that rare diseases are looked over all the time, and are trying to put an end to the isolation and capitulation that people with these diseases feel every day. Amicus Therapeutics has a plethora of positive reviews from consumers and companies alike. Whether you’re looking to expand your portfolio, seeking research for an orphan disease or making a contribution to a great cause, Amicus Therapeutics is the biopharmaceutical company to look at. Learn more about job offerings of Amicus Therapeutics at